ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,240Medicare Part D Prescriptions Filled, Including Refills

Rank: 51 out of 229

$560K Total Retail Price of All Prescriptions

Rank: 36 out of 229

522 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
21% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 522 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

7% of this provider’s 522 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

1% of this provider’s 7,100 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$68 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
LISINOPRIL 567 509 1 2
LEVOTHYROXINE SODIUM 508 481 2 1
SIMVASTATIN 390 354 3 3
LOVASTATIN 286 264 4 11
AMLODIPINE BESYLATE 273 244 5 5
FUROSEMIDE 233 215 6 8
METFORMIN HCL 201 180 7 6
CRESTOR 193 192 8 30
ATORVASTATIN CALCIUM 186 149 9 15
TRIAMTERENE-HCTZ 168 163 10 51
LOSARTAN POTASSIUM 165 150 11 12
TAMSULOSIN HCL 156 156 12 24
HYDROCHLOROTHIAZIDE 150 121 13 9
OMEPRAZOLE 142 100 14 4
GABAPENTIN 130 93 15 10
METOPROLOL TARTRATE 127 119 16 13
POTASSIUM CHLORIDE 114 93 17 18
JANUVIA 112 112 18 59
HYDROCODONE-ACETAMINOPHEN 99 71 S3 19 7
ALLOPURINOL 87 80 20 27
FINASTERIDE 82 82 21 55
OXYCODONE HCL 80 11 S2 22 37
METOPROLOL SUCCINATE 80 72 22 16
DIOVAN 78 62 24 42
ATENOLOL 75 72 25 19
RANITIDINE HCL 70 66 26 32
DILTIAZEM ER 67 67 27 123
CARVEDILOL 63 63 28 31
GLIPIZIDE 62 58 29 36
WARFARIN SODIUM 61 57 30 17
ZETIA 58 35 31 93
FLOVENT HFA 54 49 32 115
OXYCONTIN 53 0 S2 33 88
FENOFIBRATE 53 37 33 68
FLUTICASONE PROPIONATE 53 48 33 23
CYMBALTA 53 32 33 64
CELEBREX 53 51 33 71
LEVOXYL 52 37 38 148
ADVAIR DISKUS 52 38 38 47
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 12, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.